Nautilus Biotechnology Inc. has announced an agreement with the Allen Institute to explore the connection between tau protein and neurodegenerative conditions, particularly Alzheimer's disease. This collaboration will utilize Nautilus' single-molecule proteomics method, Iterative Mapping, to investigate tau proteoforms. The company's recent preprint, "Development of a method for large-scale single-molecule analysis of tau proteoforms," highlights the platform's capabilities in providing high-resolution biological insights from brain samples of Alzheimer's patients. The study presents initial validation of the method's accuracy, sensitivity, and reproducibility. The results of this collaboration have not yet been presented, as the research is ongoing.